EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study

Hsin-Yi Wang, Wei-Yu Liao, Chao-Chi Ho, Shang-Gin Wu, Ching-Yao Yang, Chia-Lin Hsu, Yen-Ting Lin, James Chih-Hsin Yang, Jin-Yuan Shih

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Hsin-Yi Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, No. 579, Sectio…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Pleural Effusion, Malignant. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Taiwan University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Inadequate tumour samples often hinder molecular testing in non-small cell lung cancer (NSCLC). Plasma-based cell-free DNA (cfDNA) sequencing has shown promise in bypassing these tissue limitations. Nevertheless, pleural effusion (PE) samples may offer a richer cfDNA source for mutation detection in patients with malignant PE. METHODS: This prospective study enrolled newly diagnosed advanced NSCLC patients with malignant PE. PE samples were collected for cfDNA NGS analysis. Meanwhile, PE cell pellet RNA was extracted for reverse transcription polymerase chain reaction (RT-PCR) for clinically relevant actionable mutations and then confirmed by Sanger sequencing. The concordance between PE cell pellet RT-PCR and PE cfDNA NGS analyses was analysed. RESULTS: Fifty patients were enrolled. The median age was 68.5 years, and the female-to-male ratio was 29:21. Most patients (74 %) were non-smokers. Notably, 45/50 patients (90 %) had actionable mutations, including EGFR exon 19 deletions (24 %), EGFR L858R mutations (36 %), HER2 exon20 insertions (10 %), ROS1 rearrangements (4 %), EGFR exon20 insertions (2 %), ALK rearrangements (4 %), RET rearrangements (2 %), KRAS G12C mutations (2 %), and CD74-NRG1 fusions (2 %). Among the 50 enrolled patients, actionable mutations were detected in 44 (88 %) by PE cfDNA NGS, 39 (78 %) by PE cell pellet Sanger sequencing, and 33 (66 %) by clinical tissue genetic testing (P = 0.031). The detection of actionable mutations from PE cfDNA NGS remained consistently high across M1a to M1c stages. CONCLUSIONS: PE cfDNA genotyping has clinical applicability for NSCLC patients and can serve as an additional source for molecular testing. Incorporating PE NGS cfDNA analysis into genetic testing enhances diagnostic yield and aids in identifying actionable mutations in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationPleural Effusion, MalignantBiomarkers, TumorCell-Free Nucleic AcidsHumansFemaleMaleAgedProspective StudiesMiddle AgedDNA Mutational AnalysisAged, 80 and overHigh-Throughput Nucleotide SequencingAdult

Stichwörter der Autor:innen

CtDNALiquid biopsyNSCLCNext generation sequencingPleural effusion cfDNA

Substanzen

Biomarkers, TumorCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, No. 579, Section 2, Yunlin Rd., Yunlin County, Douliu City 640, Taiwan; Graduate Inst…
  • Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Zhongzheng Dist., Taipei City 100, Taiwan.
  • National Taiwan University Cancer Centre, Taipei City 106, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Taiwan.
  • Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, No. 1, Section 4, Roosevelt Rd., Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chu…

Förderung

  • National Taiwan University Hospital

Zitieren

APA

Wang, H. Y., Liao, W. Y., Ho, C. C., Wu, S. G., Yang, C. Y., Hsu, C. L., Lin, Y. T., Yang, J. C., & Shih, J. Y. (2025). Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115224

Vancouver

Wang HY, Liao WY, Ho CC, Wu SG, Yang CY, Hsu CL, et al. Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115224

BibTeX
@article{Wang2025,
  author = {Wang, Hsin-Yi and Liao, Wei-Yu and Ho, Chao-Chi and Wu, Shang-Gin and Yang, Ching-Yao and Hsu, Chia-Lin and Lin, Yen-Ting and Yang, James Chih-Hsin and Shih, Jin-Yuan},
  title = {Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115224}
}
Kostenlos starten →